Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia
Saved in:
| Published in: | Haematologica - the Hematology journal |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia
- Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed/refractory acute myeloid leukemia with FMSlike tyrosine kinase 3 internal tandem duplication
- Optimal management of elderly/old Ph+ acute lymphoblastic leukemia patients
- QKI dysregulation induces extensive splicing changes in T-cell acute lymphoblastic leukemia
- Hyper-CVAD in Adults With Acute Lymphoblastic Leukemia in Ecuador: A Multicenter Retrospective Study
- Accurate automated diagnosis of B-acute lymphoblastic leukemia using deep learning and flow cytometry
- Metachronous B-Cell Acute Lymphoblastic Leukemia After Localized Neuroblastoma Treated Without Cytotoxic Therapy: A Case Report